{"id":2664,"date":"2022-07-15T22:08:33","date_gmt":"2022-07-15T22:08:33","guid":{"rendered":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/?p=2664"},"modified":"2022-07-15T22:08:33","modified_gmt":"2022-07-15T22:08:33","slug":"rvo","status":"publish","type":"post","link":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/rvo\/","title":{"rendered":"RVO"},"content":{"rendered":"\n<div class=\"wp-block-cover\"><span aria-hidden=\"true\" class=\"wp-block-cover__background has-background-dim\"><\/span><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"682\" class=\"wp-block-cover__image-background wp-image-2639\" alt=\"\" src=\"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-content\/uploads\/sites\/4\/2022\/07\/new-drawer-image-blue.png\" data-object-fit=\"cover\" srcset=\"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-content\/uploads\/sites\/4\/2022\/07\/new-drawer-image-blue.png 1024w, https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-content\/uploads\/sites\/4\/2022\/07\/new-drawer-image-blue.png?resize=300,200 300w, https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-content\/uploads\/sites\/4\/2022\/07\/new-drawer-image-blue.png?resize=768,512 768w, https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-content\/uploads\/sites\/4\/2022\/07\/new-drawer-image-blue.png?resize=572,381 572w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><div class=\"wp-block-cover__inner-container is-layout-flow wp-block-cover-is-layout-flow\">\n<h2 class=\"has-text-align-center wp-block-heading\">\u201cI suddenly noticed blurry vision in one eye, and it got much worse over the course of a couple days. My doctor diagnosed me with a retinal vein occlusion and said I can lose my vision permanently without frequent treatment.\u201d<\/h2>\n<\/div><\/div>\n\n\n\n\n<h2 class=\"has-text-align-center wp-block-heading\">WHAT IS RETINAL VEIN OCCLUSION (RVO)?<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\" \/>\n\n\n\n<p>The retina needs a constant supply of oxygen and nutrients delivered by blood vessels. In retinal vein occlusion (RVO), a blockage occurs in either the central retinal vein (CRVO) or a branch retinal vein (BRVO). As a result of the RVO, ischemia develops within the retina and VEGF levels are elevated. Patients with RVO are at risk for developing:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Macular edema: Fluid leakage into the center of the retina causing decreased vision<\/li><li>Retinal and Anterior Segment Neovascularization: Abnormal, blood vessels grow in response to ischemia and excess VEGF. Neovascularization easily\u00a0bleeds and may lead to severe vision loss and neovascular glaucoma.<\/li><\/ul>\n\n\n\n\n\n<h2 class=\"has-text-align-center wp-block-heading\">TARCOCIMAB TEDROMER (KSI-301) FOR RVO<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\" \/>\n\n\n\n<p class=\"has-text-align-center\">Our therapeutic candidate tarcocimab tedromer KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia\u00a0due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents\u00a0have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, tarcocimab tedromer KSI-301 may relieve the high treatment burden for patients, their family members, and physicians.\u00a0<\/p>\n\n\n\n<p class=\"has-text-align-center\">Tarcocimab tedromer KSI-301 is being developed towards a once every two months or longer treatment regimen.<\/p>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2664","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/posts\/2664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/comments?post=2664"}],"version-history":[{"count":0,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/posts\/2664\/revisions"}],"wp:attachment":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/media?parent=2664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/categories?post=2664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/tags?post=2664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}